BERLIN–(BUSINESS WIRE)–Regulatory News: TME Pharma N.V. (Euronext Growth Paris: ALTME), a biotechnology company focused on developing novel therapies for treatment of cancer by targeting the tumor microenvironment (TME), announces the successful closing of a €1.48 million gross private placement financing with a group of new investors. The proceeds will be used to repurchase all the outstanding convertible bonds held by Atlas Special Opportunities, LLC (ASO), thereby ending TME Pharma’s conve
Business Wire Stock Sale/Buyback News
